Testing Antimicrobial Properties of Human Lactoferrin-Derived Fragments
Abstract
:1. Introduction
2. Results
2.1. In silico Selection of Lactoferrin Fragments
2.2. Experimental Verification of Antimicrobial Properties of Lactoferrin Fragments
3. Discussion
4. Materials and Methods
4.1. Sequences
4.2. Strains and Culture Conditions
4.3. Determination of the Antimicrobial Properties of Lactoferrin Fragments
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Vorland, L.H. Lactoferrin: A Multifunctional Glycoprotein. APMIS 1999, 107, 971–981. [Google Scholar] [CrossRef] [PubMed]
- Sorensen, M.; Sorensen, S.P.L. The proteins in whey. Compte Rendu Des Trav. Du Lab. De Carlsberg Ser. Chim. 1940, 23, 55–99. [Google Scholar]
- Johanson, B. Isolation of an Iron-Containing Red Protein from Milk. Acta Chem. Scand. 1960, 14, 510–512. [Google Scholar] [CrossRef]
- Baker, E.N.; Lindley, P.F. New Perspectives on the Structure and Function of Transferrins. J. Inorg. Biochem. 1992, 47, 147–160. [Google Scholar] [CrossRef]
- Brock, J.H. Lactoferrin—50 Years On. Biochem. Cell Biol. 2012, 90, 245–251. [Google Scholar] [CrossRef] [PubMed]
- Rastogi, N.; Singh, A.; Singh, P.K.; Tyagi, T.K.; Pandey, S.; Shin, K.; Kaur, P.; Sharma, S.; Singh, T.P. Structure of Iron Saturated C-Lobe of Bovine Lactoferrin at PH 6.8 Indicates a Weakening of Iron Coordination: Structure of an Intermediate of Iron-Saturated C-Lobe. Proteins Struct. Funct. Bioinform. 2016, 84, 591–599. [Google Scholar] [CrossRef]
- Jeltsch, J.-M.; Chambon, P. The Complete Nucleotide Sequence of the Chicken Ovotransferrin MRNA. Eur. J. Biochem. 1982, 122, 291–295. [Google Scholar] [CrossRef]
- Lambert, L.A.; Perri, H.; Meehan, T.J. Evolution of Duplications in the Transferrin Family of Proteins. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2005, 140, 11–25. [Google Scholar] [CrossRef] [PubMed]
- Abe, H.; Saito, H.; Miyakawa, H.; Tamura, Y.; Shimamura, S.; Nagao, E.; Tomita, M. Heat Stability of Bovine Lactoferrin at Acidic PH. J. Dairy Sci. 1991, 74, 65–71. [Google Scholar] [CrossRef]
- Van Veen, H.A.; Geerts, M.E.J.; Van Berkel, P.H.C.; Nuijens, J.H. The Role of N-Linked Glycosylation in the Protection of Human and Bovine Lactoferrin against Tryptic Proteolysis: Tryptic Susceptibility of Lactoferrin Variants. Eur. J. Biochem. 2004, 271, 678–684. [Google Scholar] [CrossRef]
- Karav, S.; German, J.; Rouquié, C.; Le Parc, A.; Barile, D. Studying Lactoferrin N-Glycosylation. Int. J. Mol. Sci. 2017, 18, 870. [Google Scholar] [CrossRef] [Green Version]
- Niaz, B.; Saeed, F.; Ahmed, A.; Imran, M.; Maan, A.A.; Khan, M.K.I.; Tufail, T.; Anjum, F.M.; Hussain, S.; Suleria, H.A.R. Lactoferrin (LF): A Natural Antimicrobial Protein. Int. J. Food Prop. 2019, 22, 1626–1641. [Google Scholar] [CrossRef] [Green Version]
- Levay, P.; Viljoen, M. Lactoferrin: A General Review. Haematologica 1994, 80, 252–267. [Google Scholar]
- Steijns, J.M. Milk Ingredients as Nutraceuticals. Int. J. Dairy Technol. 2001, 54, 81–88. [Google Scholar] [CrossRef]
- Legrand, D. Overview of Lactoferrin as a Natural Immune Modulator. J. Pediatr. 2016, 173, S10–S15. [Google Scholar] [CrossRef] [Green Version]
- Zimecki, M.; Artym, J. Therapeutic properties of proteins and peptides from colostrum and milk. Postep. Hig. Med. Dosw. 2005, 59, 309–323. [Google Scholar]
- Sienkiewicz, M.; Jaśkiewicz, A.; Tarasiuk, A.; Fichna, J. Lactoferrin: An Overview of Its Main Functions, Immunomodulatory and Antimicrobial Role, and Clinical Significance. Crit. Rev. Food Sci. Nutr. 2022, 62, 6016–6033. [Google Scholar] [CrossRef] [PubMed]
- Gonciarz, R.L.; Renslo, A.R. Emerging Role of Ferrous Iron in Bacterial Growth and Host–Pathogen Interaction: New Tools for Chemical (Micro)Biology and Antibacterial Therapy. Curr. Opin. Chem. Biol. 2021, 61, 170–178. [Google Scholar] [CrossRef] [PubMed]
- Hood, M.I.; Skaar, E.P. Nutritional Immunity: Transition Metals at the Pathogen–Host Interface. Nat. Rev. Microbiol. 2012, 10, 525–537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Skaar, E.P.; Raffatellu, M. Metals in Infectious Diseases and Nutritional Immunity. Metallomics 2015, 7, 926–928. [Google Scholar] [CrossRef]
- Carver, P.L. The Battle for Iron between Humans and Microbes. Curr. Med. Chem. 2018, 25, 85–96. [Google Scholar] [CrossRef] [PubMed]
- Ellison, R.T.; Giehl, T.J.; LaForce, F.M. Damage of the Outer Membrane of Enteric Gram-Negative Bacteria by Lactoferrin and Transferrin. Infect. Immun. 1988, 56, 2774–2781. [Google Scholar] [CrossRef] [Green Version]
- Roussel-Jazédé, V.; Jongerius, I.; Bos, M.P.; Tommassen, J.; van Ulsen, P. NalP-Mediated Proteolytic Release of Lactoferrin-Binding Protein B from the Meningococcal Cell Surface. Infect. Immun. 2010, 78, 3083–3089. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morgenthau, A.; Beddek, A.; Schryvers, A.B. The Negatively Charged Regions of Lactoferrin Binding Protein B, an Adaptation against Anti-Microbial Peptides. PLoS ONE 2014, 9, e86243. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ostan, N.K.H.; Yu, R.-H.; Ng, D.; Lai, C.C.-L.; Pogoutse, A.K.; Sarpe, V.; Hepburn, M.; Sheff, J.; Raval, S.; Schriemer, D.C.; et al. Lactoferrin Binding Protein B—A Bi-Functional Bacterial Receptor Protein. PLoS Pathog. 2017, 13, e1006244. [Google Scholar] [CrossRef] [Green Version]
- van der Strate, B.W.A.; Beljaars, L.; Molema, G.; Harmsen, M.C.; Meijer, D.K.F. Antiviral Activities of Lactoferrin. Antivir. Res. 2001, 52, 225–239. [Google Scholar] [CrossRef]
- Serrano, G.; Kochergina, I.; Albors, A.; Diaz, E.; Oroval, M.; Hueso, G.; Serrano, J.M. Liposomal Lactoferrin as Potential Preventative and Cure for COVID-19. Int. J. Res. Health Sci. 2020, 8, 8–15. [Google Scholar] [CrossRef]
- Elzoghby, A.O.; Abdelmoneem, M.A.; Hassanin, I.A.; Abd Elwakil, M.M.; Elnaggar, M.A.; Mokhtar, S.; Fang, J.-Y.; Elkhodairy, K.A. Lactoferrin, a Multi-Functional Glycoprotein: Active Therapeutic, Drug Nanocarrier & Targeting Ligand. Biomaterials 2020, 263, 120355. [Google Scholar] [CrossRef] [PubMed]
- Pietrantoni, A.; Fortuna, C.; Remoli, M.; Ciufolini, M.; Superti, F. Bovine Lactoferrin Inhibits Toscana Virus Infection by Binding to Heparan Sulphate. Viruses 2015, 7, 480–495. [Google Scholar] [CrossRef] [Green Version]
- Fernandes, K.E.; Carter, D.A. The Antifungal Activity of Lactoferrin and Its Derived Peptides: Mechanisms of Action and Synergy with Drugs against Fungal Pathogens. Front. Microbiol. 2017, 8, 2. [Google Scholar] [CrossRef] [Green Version]
- Acosta-Zaldívar, M.; Andrés, M.T.; Rego, A.; Pereira, C.S.; Fierro, J.F.; Côrte-Real, M. Human Lactoferrin Triggers a Mitochondrial- and Caspase-Dependent Regulated Cell Death in Saccharomyces Cerevisiae. Apoptosis 2016, 21, 163–173. [Google Scholar] [CrossRef]
- Andrés, M.T.; Acosta-Zaldívar, M.; Fierro, J.F. Antifungal Mechanism of Action of Lactoferrin: Identification of H+-ATPase (P3A-Type) as a New Apoptotic-Cell Membrane Receptor. Antimicrob. Agents Chemother. 2016, 60, 4206–4216. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gibbons, J.A. Lactoferrin and Cancer in Different Cancer Models. Front. Biosci. 2011, S3, 1080. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Y.; Lima, C.F.; Rodrigues, L.R. Anticancer Effects of Lactoferrin: Underlying Mechanisms and Future Trends in Cancer Therapy. Nutr. Rev. 2014, 72, 763–773. [Google Scholar] [CrossRef] [Green Version]
- Siqueiros-Cendón, T.; Arévalo-Gallegos, S.; Iglesias-Figueroa, B.F.; García-Montoya, I.A.; Salazar-Martínez, J.; Rascón-Cruz, Q. Immunomodulatory Effects of Lactoferrin. Acta Pharmacol. Sin. 2014, 35, 557–566. [Google Scholar] [CrossRef]
- García-Montoya, I.A.; Cendón, T.S.; Arévalo-Gallegos, S.; Rascón-Cruz, Q. Lactoferrin a Multiple Bioactive Protein: An Overview. Biochim. Biophys. Acta BBA-Gen. Subj. 2012, 1820, 226–236. [Google Scholar] [CrossRef]
- Le, C.-F.; Fang, C.-M.; Sekaran, S.D. Intracellular Targeting Mechanisms by Antimicrobial Peptides. Antimicrob. Agents Chemother. 2017, 61, e02340-16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marquette, A.; Bechinger, B. Biophysical Investigations Elucidating the Mechanisms of Action of Antimicrobial Peptides and Their Synergism. Biomolecules 2018, 8, 18. [Google Scholar] [CrossRef] [Green Version]
- Kumar, P.; Kizhakkedathu, J.; Straus, S. Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo. Biomolecules 2018, 8, 4. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Q.-Y.; Yan, Z.-B.; Meng, Y.-M.; Hong, X.-Y.; Shao, G.; Ma, J.-J.; Cheng, X.-R.; Liu, J.; Kang, J.; Fu, C.-Y. Antimicrobial Peptides: Mechanism of Action, Activity and Clinical Potential. Mil. Med. Res. 2021, 8, 48. [Google Scholar] [CrossRef]
- Gruden, Š.; Poklar Ulrih, N. Diverse Mechanisms of Antimicrobial Activities of Lactoferrins, Lactoferricins, and Other Lactoferrin-Derived Peptides. Int. J. Mol. Sci. 2021, 22, 11264. [Google Scholar] [CrossRef]
- Elbarbary, H.A.; Abdou, A.M.; Park, E.Y.; Nakamura, Y.; Mohamed, H.A.; Sato, K. Novel Antibacterial Lactoferrin Peptides Generated by Rennet Digestion and Autofocusing Technique. Int. Dairy J. 2010, 20, 646–651. [Google Scholar] [CrossRef]
- Flores-Villaseñor, H.; Canizalez-Román, A.; Reyes-Lopez, M.; Nazmi, K.; de la Garza, M.; Zazueta-Beltrán, J.; León-Sicairos, N.; Bolscher, J.G.M. Bactericidal Effect of Bovine Lactoferrin, LFcin, LFampin and LFchimera on Antibiotic-Resistant Staphylococcus aureus and Escherichia coli. BioMetals 2010, 23, 569–578. [Google Scholar] [CrossRef]
- Groenink, J.; Walgreen-Weterings, E.; ’t Hof, W.; Veerman, E.C.I.; Nieuw Amerongen, A.V. Cationic Amphipathic Peptides, Derived from Bovine and Human Lactoferrins, with Antimicrobial Activity against Oral Pathogens. FEMS Microbiol. Lett. 1999, 179, 217–222. [Google Scholar] [CrossRef]
- León-Calvijo, M.A.; Leal-Castro, A.L.; Almanzar-Reina, G.A.; Rosas-Pérez, J.E.; García-Castañeda, J.E.; Rivera-Monroy, Z.J. Antibacterial Activity of Synthetic Peptides Derived from Lactoferricin against Escherichia coli ATCC 25922 and Enterococcus faecalis ATCC 29212. BioMed Res. Int. 2015, 2015, 1–8. [Google Scholar] [CrossRef] [Green Version]
- Yamauchi, K.; Tomita, M.; Giehl, T.J.; Ellison, R.T. Antibacterial Activity of Lactoferrin and a Pepsin-Derived Lactoferrin Peptide Fragment. Infect. Immun. 1993, 61, 719–728. [Google Scholar] [CrossRef] [Green Version]
- Hoek, K.S.; Milne, J.M.; Grieve, P.A.; Dionysius, D.A.; Smith, R. Antibacterial Activity in Bovine Lactoferrin-Derived Peptides. Antimicrob. Agents Chemother. 1997, 41, 54–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Samuelsen, Ã.; Haukland, H.H.; Ulvatne, H.; Vorland, L.H. Anti-Complement Effects of Lactoferrin-Derived Peptides. FEMS Immunol. Med. Microbiol. 2004, 41, 141–148. [Google Scholar] [CrossRef] [PubMed]
- Tomita, M.; Takase, M.; Wakabayashi, H.; Bellamy, W. Antimicrobial Peptides of Lactoferrin. In Lactoferrin Structure and Function; Hutchens, T.W., Rumball, S.V., Lönnerdal, B., Eds.; Advances in, Experimental Medicine and Biology; Springer: Boston, MA, USA, 1994; Volume 357, pp. 209–218. ISBN 978-0-306-44734-1. [Google Scholar]
- Sarhadi, H.; Jahandar, M.H.; Tanhaeian, A. Evaluation of Antibacterial Properties of Chimeric Bovine Lactoferrin Peptide for Inhibition of Food and Plant Pathogens. Int. J. Infect. 2020, 7, e104594. [Google Scholar] [CrossRef]
- Nibbering, P.H.; Ravensbergen, E.; Welling, M.M.; van Berkel, L.A.; van Berkel, P.H.C.; Pauwels, E.K.J.; Nuijens, J.H. Human Lactoferrin and Peptides Derived from Its N Terminus Are Highly Effective against Infections with Antibiotic-Resistant Bacteria. Infect. Immun. 2001, 69, 1469–1476. [Google Scholar] [CrossRef] [Green Version]
- Dijkshoorn, L.; Brouwer, C.P.J.M.; Bogaards, S.J.P.; Nemec, A.; van den Broek, P.J.; Nibbering, P.H. The Synthetic N-Terminal Peptide of Human Lactoferrin, HLF(1-11), Is Highly Effective against Experimental Infection Caused by Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2004, 48, 4919–4921. [Google Scholar] [CrossRef] [Green Version]
- Denardi, L.B.; de Arruda Trindade, P.; Weiblen, C.; Ianiski, L.B.; Stibbe, P.C.; Pinto, S.C.; Santurio, J.M. In Vitro Activity of the Antimicrobial Peptides H-Lf1-11, MSI-78, LL-37, Fengycin 2B, and Magainin-2 against Clinically Important Bacteria. Braz. J. Microbiol. 2022, 53, 171–177. [Google Scholar] [CrossRef]
- van der Kraan, M.I.A.; Groenink, J.; Nazmi, K.; Veerman, E.C.I.; Bolscher, J.G.M.; Nieuw Amerongen, A.V. Lactoferrampin: A Novel Antimicrobial Peptide in the N1-Domain of Bovine Lactoferrin. Peptides 2004, 25, 177–183. [Google Scholar] [CrossRef]
- van der Kraan, M.I.A.; van Marle, J.; Nazmi, K.; Groenink, J.; van ’t Hof, W.; Veerman, E.C.I.; Bolscher, J.G.M.; Amerongen, A.V.N. Ultrastructural Effects of Antimicrobial Peptides from Bovine Lactoferrin on the Membranes of Candida Albicans and Escherichia coli. Peptides 2005, 26, 1537–1542. [Google Scholar] [CrossRef]
- Tu, Y.-H.; Ho, Y.-H.; Chuang, Y.-C.; Chen, P.-C.; Chen, C.-S. Identification of Lactoferricin B Intracellular Targets Using an Escherichia coli Proteome Chip. PLoS ONE 2011, 6, e28197. [Google Scholar] [CrossRef] [Green Version]
- Ho, Y.-H.; Sung, T.-C.; Chen, C.-S. Lactoferricin B Inhibits the Phosphorylation of the Two-Component System Response Regulators BasR and CreB. Mol. Cell. Proteom. 2012, 11, M111.014720. [Google Scholar] [CrossRef] [Green Version]
- Shinoda, I.; Takase, M.; Fukuwatari, Y.; Shimamura, S.; Köller, M.; König, W. Effects of Lactoferrin and Lactoferricin® on the Release of Interleukin 8 from Human Polymorphonuclear Leukocytes. Biosci. Biotechnol. Biochem. 1996, 60, 521–523. [Google Scholar] [CrossRef] [Green Version]
- Elass-Rochard, E.; Roseanu, A.; Legrand, D.; Trif, M.; Salmon, V.; Motas, C.; Montreuil, J.; Spik, G. Lactoferrin-Lipopolysaccharide Interaction: Involvement of the 28–34 Loop Region of Human Lactoferrin in the High-Affinity Binding to Escherichia coli 055B5 Lipopolysaccharide. Biochem. J. 1995, 312, 839–845. [Google Scholar] [CrossRef] [Green Version]
- Aguilera, O.; Ostolaza, H. Permeabilizing Action of an Antimicrobial Lactoferricin-Derived Peptide on Bacterial and Arti¢cial Membranes. FEBS Lett. 1999, 462, 273–277. [Google Scholar] [CrossRef] [Green Version]
- Van Berkel, P.H.C.; Geerts, E.J.M.; Van Veen, A.H.; Mericskay, M.; De Boer, A.H.; Nuijens, H.J. N-Terminal Stretch Arg2, Arg3, Arg4 and Arg5 of Human Lactoferrin Is Essential for Binding to Heparin, Bacterial Lipopolysaccharide, Human Lysozyme and DNA. Biochem. J. 1997, 328, 145–151. [Google Scholar] [CrossRef] [Green Version]
- Pjm Brouwer, C. Structure-Activity Relationship Study of Synthetic Variants Derived from the Highly Potent Human Antimicrobial Peptide HLF(1-11). Cohesive J. Microbiol. Infect. Dis. 2018, 1. [Google Scholar] [CrossRef] [Green Version]
- van der Does, A.M.; Bogaards, S.J.P.; Jonk, L.; Wulferink, M.; Velders, M.P.; Nibbering, P.H. The Human Lactoferrin-Derived Peptide HLF1-11 Primes Monocytes for an Enhanced TLR-Mediated Immune Response. BioMetals 2010, 23, 493–505. [Google Scholar] [CrossRef]
- Weinberg, E. Antibiotic Properties and Applications of Lactoferrin. Curr. Pharm. Des. 2007, 13, 801–811. [Google Scholar] [CrossRef] [Green Version]
- González-Chávez, S.A.; Arévalo-Gallegos, S.; Rascón-Cruz, Q. Lactoferrin: Structure, Function and Applications. Int. J. Antimicrob. Agents 2009, 33, 301.e1–301.e8. [Google Scholar] [CrossRef]
- EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on bovine lactoferrin. EFSA J. 2012, 10, 2701. [Google Scholar] [CrossRef] [Green Version]
- Ke, C.; Lan, Z.; Hua, L.; Ying, Z.; Humina, X.; Jia, S.; Weizheng, T.; Ping, Y.; Lingying, C.; Meng, M. Iron Metabolism in Infants: Influence of Bovine Lactoferrin from Iron-Fortified Formula. Nutrition 2015, 31, 304–309. [Google Scholar] [CrossRef]
- Hao, L.; Shan, Q.; Wei, J.; Ma, F.; Sun, P. Lactoferrin: Major Physiological Functions and Applications. Curr. Protein Pept. Sci. 2018, 20, 139–144. [Google Scholar] [CrossRef]
- Burdukiewicz, M.; Sidorczuk, K.; Rafacz, D.; Pietluch, F.; Chilimoniuk, J.; Rödiger, S.; Gagat, P. Proteomic Screening for Prediction and Design of Antimicrobial Peptides with AmpGram. Int. J. Mol. Sci. 2020, 21, 4310. [Google Scholar] [CrossRef]
- Sidorczuk, K.; Gagat, P.; Pietluch, F.; Kała, J.; Rafacz, D.; Bąkała, L.; Słowik, J.; Kolenda, R.; Rödiger, S.; Fingerhut, L.C.H.W.; et al. Benchmarks in Antimicrobial Peptide Prediction Are Biased Due to the Selection of Negative Data. Brief. Bioinform. 2022, 23, bbac343. [Google Scholar] [CrossRef]
- Andrade, F.F.; Silva, D.; Rodrigues, A.; Pina-Vaz, C. Colistin Update on Its Mechanism of Action and Resistance, Present and Future Challenges. Microorganisms 2020, 8, 1716. [Google Scholar] [CrossRef]
- El-Sayed Ahmed, M.A.E.-G.; Zhong, L.-L.; Shen, C.; Yang, Y.; Doi, Y.; Tian, G.-B. Colistin and Its Role in the Era of Antibiotic Resistance: An Extended Review (2000–2019). Emerg. Microbes Infect. 2020, 9, 868–885. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khamesipour, F.; Hashemian, S.M.; Velayati, A.A.; Tabarsi, P. A Review of Teicoplanin Used in the Prevention and Treatment of Serious Infections Caused by Gram-Positive Bacteria and Compared Its Effects with Some Other Antibiotics. Biomed. Pharmacol. J. 2015, 8, 513–521. [Google Scholar]
- Yushchuk, O.; Ostash, B.; Truman, A.W.; Marinelli, F.; Fedorenko, V. Teicoplanin Biosynthesis: Unraveling the Interplay of Structural, Regulatory, and Resistance Genes. Appl. Microbiol. Biotechnol. 2020, 104, 3279–3291. [Google Scholar] [CrossRef] [PubMed]
- Ramamourthy, G.; Vogel, H.J. Antibiofilm Activity of Lactoferrin-Derived Synthetic Peptides against Pseudomonas Aeruginosa PAO1. Biochem. Cell Biol. 2021, 99, 138–148. [Google Scholar] [CrossRef]
- Gagat, P.; Duda-Madej, A.; Ostrówka, M.; Pietluch, F.; Seniuk, A.; Mackiewicz, P.; Burdukiewicz, M. Testing Antimicrobial Properties of Selected Short Amyloids. Int. J. Mol. Sci. 2023, 24, 804. [Google Scholar] [CrossRef]
- Powers, J.C.; Asgian, J.L.; Ekici, Ö.D.; James, K.E. Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases. Chem. Rev. 2002, 102, 4639–4750. [Google Scholar] [CrossRef]
- Vaara, M. Agents That Increase the Permeability of the Outer Membrane. Microbiol. Rev. 1992, 56, 395–411. [Google Scholar] [CrossRef]
- Paterson, J.R.; Beecroft, M.S.; Mulla, R.S.; Osman, D.; Reeder, N.L.; Caserta, J.A.; Young, T.R.; Pettigrew, C.A.; Davies, G.E.; Williams, J.A.G.; et al. Insights into the Antibacterial Mechanism of Action of Chelating Agents by Selective Deprivation of Iron, Manganese, and Zinc. Appl. Environ. Microbiol. 2022, 88, e01641-21. [Google Scholar] [CrossRef]
- Lebeaux, D.; Leflon-Guibout, V.; Ghigo, J.-M.; Beloin, C. In Vitro Activity of Gentamicin, Vancomycin or Amikacin Combined with EDTA or L-Arginine as Lock Therapy against a Wide Spectrum of Biofilm-Forming Clinical Strains Isolated from Catheter-Related Infections. J. Antimicrob. Chemother. 2015, 70, 1704–1712. [Google Scholar] [CrossRef] [Green Version]
- The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. 2020. Available online: http://www.eucast.org (accessed on 19 June 2023).
- Xu, J.; Li, F.; Leier, A.; Xiang, D.; Shen, H.-H.; Marquez Lago, T.T.; Li, J.; Yu, D.-J.; Song, J. Comprehensive Assessment of Machine Learning-Based Methods for Predicting Antimicrobial Peptides. Brief. Bioinform. 2021, 22, bbab083. [Google Scholar] [CrossRef]
Peptide | Gram-positive (+) and Gram-negative (−) Bacterial Strain (MIC-µg/mL) | Ref | |
---|---|---|---|
bLF 1-20 | +B. subtilis NBRC 3134 (50) | −E. coli NBRC 3301 (50) | [42] |
bLF 17-30 | +S. aureus ATCC 25923 (76.8) + MRSA (38.4) | −E. coli EPEC E2348/69 (76.8) −E. coli MREPEC (38.4) −E. coli EHEC O157:H7 (38.4) | [43] |
bLF 17-30 | +S. aureus HG386 (75) +S. mutans HG455 (37) +S. sobrinus OB50 (37) +S. salivarius HG475 (37) | −E. coli K12 (37) −K. pneumoniae HG389 (75) −P. intermedia OB51 (18) | [44] |
bLF 20-30 | +B. subtilis NBRC 3134 (6.25) | −E. coli NBRC 3301 (25) | [42] |
bLF 17-31 | +E. faecalis ATCC 29212 (50) | −E. coli ATCC 25922 (50) | [45] |
bLF 19-37 | −P. intermedia OB51 (75) | [44] | |
bLF 17-41 (bLFcin) | +L. monocytogenes EGD (1.6) +L. monocytogenes 4b maritime (6.6) +S. aureus ATCC 29213 (6.6) | −E. coli K-12 (1.6) 1 −E. coli CL99 (8.5) 1 −S. Typhimurium SL696 (13) 1 −S. Montevideo SL5222 (8) 1 −E. coli ATCC 25922 (3.3) −P. aeruginosa ATCC 2783 (3.3) −P. aeruginosa PAO-1 (3.3) | [46] |
+B. cereus ACM 446 (18.75) +S. aureus NCTC 6571 (18.75) +L. monocytogenes NCTC 7973 (6.25) | −E. coli O:9 (18.75) −E. coli L361 (12.5) −S. Salford IMVS 1710 (12.5) | [47] | |
−E. coli ATCC 25922 (30) | [48] | ||
+E. faecalis ATCC 29212 (100) | −E. coli ATCC 25922 (100) | [45] | |
+S. aureus JCM-2179 (3) +S. mutans JCM-5705T (2) +L. monocytogenes JCM-7673 (0.3) +C. renale JCM-1322 (0.6) +B. subtilis ATCC-6633 (0.6) +C. perfringens ATCC-6013 (12) | −E. coli 0111 (6) −E. coli IIO-861 (6) −S. Enteritidis 110-604 (12) −K. pneumoniae JCM-i662T (9) −P. vulgaris JCM-i668T (12) −Y. enterocolitica 110-981 (6) −P. aeruginosa IFO-3446 (9) | [49] | |
bLF 265-284 (bLFampin) | +S. aureus ATCC 25923 (47.8) + MRSA (47.8) | −E. coli EPEC E2348/69 (47.8) −E. coli MREPEC (47.8) −E. coli EHEC O157:H7 (95.6) | [43] |
bLF 269-288 | +B. subtilis NBRC 3134 (50) | −E. coli NBRC 3301 (50) | [42] |
bLF 343-351 | +B. subtilis NBRC 3134 (50) | −E. coli NBRC 3301 (100) | [42] |
bLF chimera 2 | +S. aureus ATCC25923 (15.125) +E. faecalis ATCC 29212 (15.125) +L. monocytogenes ATCC 19111 (7.56) | −E. coli ATCC 25922 (30.25) −S. Typhimurium ATCC 14028 (7.56) | [50] |
+S. aureus ATCC 25923 (4.4) + MRSA (43.8) | −E. coli EPEC E2348/69 (4.4) −E. coli MREPEC (4.4) −E. coli EHEC O157:H7 (4.4) | [43] | |
hLF 1-11 | +S. aureus 2141 (6.85) +L. monocytogenes EGD (6.85) | −K. pneumoniae ATCC 43816 (6.85) −E. coli O54 (6.85) | [51] |
−A. baumannii LUH 6034, 7858, 7312 (12.33) −A. baumannii RUH 875, 134 (12.33) | [52] | ||
+E. faecalis ATCC 29212 (100) | −E. coli ATCC 25922 (25) | [45] | |
−A. baumannii (40) | [53] | ||
hLF 17-30 | −P. intermedia OB51 (18) | [44] | |
hLF 1-47 (hLFcin) | −E. coli 0111 (100) | [49] | |
hLF hydrolysate | −E. coli 0111 (100) | [49] |
Peptide | Sequence | MW | pI | AMP Probability |
---|---|---|---|---|
hLF 1-11 | GRRRRSVQWCA | 1374.59 | 12.00 | 0.9892 |
hLF 397-412 | GYVYTAGKCGLVPVLA | 1610.93 | 8.18 | 1.0000 |
hLF 448-412 | LTWNSVKGKKSCHTAVD | 1874.14 | 9.20 | 0.9817 |
hLF 668-683 | VAGITNLKKCSTSPLL | 1644.99 | 9.31 | 0.9862 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ostrówka, M.; Duda-Madej, A.; Pietluch, F.; Mackiewicz, P.; Gagat, P. Testing Antimicrobial Properties of Human Lactoferrin-Derived Fragments. Int. J. Mol. Sci. 2023, 24, 10529. https://doi.org/10.3390/ijms241310529
Ostrówka M, Duda-Madej A, Pietluch F, Mackiewicz P, Gagat P. Testing Antimicrobial Properties of Human Lactoferrin-Derived Fragments. International Journal of Molecular Sciences. 2023; 24(13):10529. https://doi.org/10.3390/ijms241310529
Chicago/Turabian StyleOstrówka, Michał, Anna Duda-Madej, Filip Pietluch, Paweł Mackiewicz, and Przemysław Gagat. 2023. "Testing Antimicrobial Properties of Human Lactoferrin-Derived Fragments" International Journal of Molecular Sciences 24, no. 13: 10529. https://doi.org/10.3390/ijms241310529